TCG Crossover Management, LLC
About TCG Crossover Management, LLC’s 13F portfolio
TCG Crossover Management, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , TCG Crossover Management, LLC reported $4.2B across 54 US-listed positions (). Its largest position is ABIVAX SA AMERICAN DEPOSITARY SHARES (ABVX) at 19% of the reported book, and its ten biggest holdings make up 57% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: ABVX ABIVAX SA AMERICAN DEPOSITARY SHARES | $80.65 −3.79% | 19% | 6.0M | $800.6M |
| 2 | NASDAQ: TNGX TANGO THERAPEUTICS INC | $22.71 +3.75% | 6.8% | 9.1M | $283.9M |
| 3 | NASDAQ: CGON CG ONCOLOGY INC | $81.90 +2.38% | 6.3% | 3.7M | $260.8M |
| 4 | NASDAQ: COGT COGENT BIOSCIENCES INC | $27.74 −0.25% | 4.5% | 4.9M | $187.9M |
| 5 | NASDAQ: IMVT IMMUNOVANT INC | $32.52 −1.96% | 4.1% | 4.5M | $171.8M |
| 6 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | $97.63 −3.77% | 4.1% | 1.9M | $168.7M |
| 7 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | $84.83 +1.01% | 3.9% | 1.7M | $163.4M |
| 8 | NASDAQ: MIRM MIRUM PHARMACEUTICALS INC | $95.51 +3.27% | 3.0% | 1.1M | $124.3M |
| 9 | NASDAQ: ZLAB ZAI LAB LTD-ADR | $21.92 −0.86% | 2.8% | 6.1M | $116.6M |
| 10 | NASDAQ: AMLX AMYLYX PHARMACEUTICALS INC | $26.20 −1.58% | 2.7% | 6.2M | $112.1M |
| 11 | NASDAQ: GLUE MONTE ROSA THERAPEUTICS INC | $8.91 −1.76% | 2.7% | 4.6M | $111.9M |
| 12 | NASDAQ: BCRX BIOCRYST PHARMACEUTICALS INC | $7.32 +0.27% | 2.6% | 11.0M | $110.2M |
| 13 | NASDAQ: VOR VOR BIOPHARMA INC | $18.52 +3.87% | 2.5% | 5.7M | $104.4M |
| 14 | NASDAQ: TYRA TYRA BIOSCIENCES INC | $19.73 +0.61% | 2.5% | 3.2M | $103.8M |
| 15 | NASDAQ: DYN DYNE THERAPEUTICS INC | $16.03 +1.01% | 2.5% | 4.6M | $102.5M |
| 16 | NASDAQ: IRON DISC MEDICINE INC | $76.11 −2.40% | 2.4% | 1.3M | $98.1M |
| 17 | NASDAQ: RLAY RELAY THERAPEUTICS INC | $15.91 −3.63% | 1.9% | 4.3M | $80.0M |
| 18 | NASDAQ: SVRA SAVARA INC | $5.21 +10.38% | 1.8% | 12.4M | $76.2M |
| 19 | NASDAQ: AURA AURA BIOSCIENCES INC | $6.98 −2.24% | 1.6% | 9.5M | $67.7M |
| 20 | NASDAQ: RVMD REVOLUTION MEDICINES INC | $159.43 −0.24% | 1.5% | 341K | $63.8M |
| 21 | NASDAQ: TRAX FIRST TRACKS BIOTHERAPEUTICS | — — | 1.4% | 2.9M | $58.3M |
| 22 | NASDAQ: KOD KODIAK SCIENCES INC | $97.90 +0.09% | 1.4% | 1.4M | $56.3M |
| 23 | NASDAQ: AVTX AVALO THERAPEUTICS INC | $6.75 +0.75% | 1.3% | 3.0M | $55.8M |
| 24 | NASDAQ: LBRX LB PHARMACEUTICALS INC | $40.04 −0.05% | 1.1% | 1.4M | $47.0M |
| 25 | NASDAQ: IPSC CENTURY THERAPEUTICS INC | $1.32 −4.35% | 1.0% | 17.8M | $43.4M |
Showing 1–25 of 54 positions on this page reported in this 13F.
- Healthcare97%
- NewZLABZAI LAB LTD-ADR—$116.6M
- NewAURAAURA BIOSCIENCES INC—$67.7M
- NewTRAXFIRST TRACKS BIOTHERAPEUTICS—$58.3M
- AddedAVTXAVALO THERAPEUTICS INC+309%$55.8M
- NewEDITEDITAS MEDICINE INC—$36.0M
- NewPHVSPHARVARIS BV—$34.9M
- NewIFRXINFLARX N V—$32.5M
- NewALTALTIMMUNE INC—$30.4M
- NewAKTSAKTIS ONCOLOGY INC—$22.5M
- NewFBRXFORTE BIOSCIENCES INC—$19.6M
- ReducedABVXABIVAX SA AMERICAN DEPOSITARY SHARES−7.3%$800.6M
- ReducedTNGXTANGO THERAPEUTICS INC−13.8%$283.9M
- ReducedCOGTCOGENT BIOSCIENCES INC−1.9%$187.9M
- ReducedRVMDREVOLUTION MEDICINES INC−40.9%$63.8M
- ReducedLBRXLB PHARMACEUTICALS INC−21.3%$47.0M
- ReducedBHVNBIOHAVEN LTD−61.6%$26.5M
- ReducedALXOALX ONCOLOGY HOLDINGS INC−56.5%$11.7M
- ReducedTRDAENTRADA THERAPEUTICS INC−53.7%$7.8M
- ReducedARVNARVINAS HOLDING CO LLC−70.4%$5.9M
- SoldURGNUROGEN PHARMA LTD−100%—
Reading TCG Crossover Management, LLC’s 13F portfolio
TCG Crossover Management, LLC’s $4.2B 13F book is spread across 54 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 57%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are ABVX, TNGX, CGON, COGT and IMVT, led by ABIVAX SA AMERICAN DEPOSITARY SHARES (ABVX) at 19% of the portfolio. The heaviest sector exposure is Healthcare (97%).
What TCG Crossover Management, LLC changed last quarter
Between 2026-03-31 and Q2 2026, TCG Crossover Management, LLC was roughly balanced between buying and selling: it opened 12 new positions and added to 2 more, while trimming 9 and closing 7 outright. Against a 54-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ZAI LAB LTD-ADR (ZLAB), and its biggest reduction was ABIVAX SA AMERICAN DEPOSITARY SHARES (ABVX).
What a 13F does and doesn’t reveal
A 13F captures only TCG Crossover Management, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names TCG Crossover Management, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. TCG Crossover Management, LLC's profile on this page is built directly from those filings.
How current is the 13F data on TCG Crossover Management, LLC's page?
It reflects TCG Crossover Management, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When TCG Crossover Management, LLC files its next quarterly report, this page refreshes automatically.
Can I see TCG Crossover Management, LLC's complete list of holdings?
This page highlights TCG Crossover Management, LLC's largest positions rather than all 54 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under TCG Crossover Management, LLC's filings.
Does a 13F show everything TCG Crossover Management, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of TCG Crossover Management, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why TCG Crossover Management, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

